IOTA Diagnostic: Making Women's Health Screening More Accessible Through Innovation

Problem

Cervical cancer screening remains challenging for many women because of discomfort, privacy concerns, limited awareness and inadequate access to diagnostic facilities. Conventional biological sample collection can also require trained personnel, specialised equipment and cold-chain logistics, limiting diagnostic access in remote communities. IOTA aims to address these barriers through patient-friendly self-sampling and simplified sample transportation.

Product

IOTA's two key innovations are M-Strip™ and BioSampler®. M-Strip is designed to collect menstrual fluid for HPV-related cervical cancer screening, while BioSampler uses dried bio-specimen matrix technology to collect, preserve and transport microlitre quantities of biological samples at ambient temperature. Together, they target more accessible and decentralised diagnostic testing.

Proof

The company reports CDSCO approval for its BioSampler technology and M-Strip product. Its recent operational updates also describe a partnership with the Government of Odisha for women's health screening initiatives. In January 2026, the company reported that approximately 2,500 M-Strip units had been sold during its pilot phase and that the product was listed on Tata 1mg.

People

IOTA Diagnostic was founded by Vaibhav Shitole, Founder and CEO, alongside co-founders Pradeep Verma, Prasoon Kumar and Kaushik Chaudhary. The multidisciplinary team brings together expertise in biotechnology, engineering, product design, clinical research and medical-device development.

Purse

IOTA has received early-stage support from DST-STBI Vadodara and IIMA Ventures to advance product development and clinical translation. In January 2026, the company secured additional investment from BizDateUp Technologies, although the investment amount was not publicly disclosed. Its founder subsequently referred to approximately ₹3.5 crore in follow-on funding.

Plan

IOTA plans to expand M-Strip deployment across rural and underserved communities, strengthen clinical adoption and increase access to cervical cancer screening. The company is also working to extend BioSampler technology into additional diagnostic applications, pursue international patent protection and prepare for entry into regulated global markets.

Why it matters

IOTA Diagnostic is addressing two important challenges in healthcare: improving women's access to cervical cancer screening and simplifying biological sample collection. Its innovations could help make diagnostic services more private, convenient and accessible, particularly in communities where conventional testing infrastructure remains limited.

Disclaimer: This profile is based on publicly available company information, official announcements and investor disclosures reviewed as of 2 November 2026.